Skip to content

Study · Randomized controlled trial · n = 22 · 2015

7 results

The activity of satellite cells and myonuclei following 8 weeks of strength training in young men with suppressed testosterone levels.

Kvorning T, Kadi F, Schjerling P, Andersen M, Brixen K, Suetta C, Madsen K

Acta physiologica (Oxford, England)15 Nov 2014Cited by 15 (Europe PMC)

PMID25294097 (opens in a new tab)DOI10.1111/apha.12404 (opens in a new tab)PepBankPUB-25294097
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In young men, resting testosterone was 10-20 times lower with goserelin than placebo.

    In plain wordsIn young men, resting testosterone was 10-20 times lower with goserelin than placebo.

    Peptide
    Goserelin
    Outcome
    DecreaseResting testosterone
    Study

    n = 22

    Comparator
    Placebo
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Resting testosterone, times lower than placebo
    10 to 20 times
    goserelin versus placebo

    Source sentences

    Summary
    Testosterone resting level in goserelin was 10-20 times lower compared with placebo, and the training-induced increase in the level of testosterone was abolished in goserelin.
    3 context sentences
    Summary · context
    Twenty-two moderately trained young men participated in this randomized, placebo-controlled, and double-blinded intervention study.
    Summary · context
    The participants were randomized to treatment with a GnRH analogue, goserelin (n = 12), which suppresses testosterone or placebo (n = 10) for 12 weeks.
    Summary · context
    The strength training period of 8 weeks started after 4 weeks of treatment and included exercises for all major muscles.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In young men, goserelin abolished the training-induced testosterone increase.

    In plain wordsIn young men, goserelin abolished the training-related testosterone increase seen with placebo.

    Peptide
    Goserelin
    Outcome
    DecreaseTraining-induced testosterone increase
    Study

    n = 22

    Comparator
    Placebo
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Testosterone resting level in goserelin was 10-20 times lower compared with placebo, and the training-induced increase in the level of testosterone was abolished in goserelin.
    3 context sentences
    Summary · context
    Twenty-two moderately trained young men participated in this randomized, placebo-controlled, and double-blinded intervention study.
    Summary · context
    The participants were randomized to treatment with a GnRH analogue, goserelin (n = 12), which suppresses testosterone or placebo (n = 10) for 12 weeks.
    Summary · context
    The strength training period of 8 weeks started after 4 weeks of treatment and included exercises for all major muscles.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In young men, type II myonuclear numbers remained unchanged with training under goserelin but increased by 12% under placebo (P < 0.05).

    In plain wordsIn young men, type II myonuclear numbers remained unchanged with training under goserelin but increased by 12% under placebo.

    Peptide
    Goserelin
    Outcome
    DecreaseTraining-induced increase in type II myonuclear number
    Study

    n = 22

    Comparator
    Placebo
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Training-induced increase in type II myonuclear number
    12%
    placebo; P < 0.05

    Source sentences

    Summary
    Training increased satellite cells number in type II fibres by 20% in placebo and by 52% in goserelin (P < 0.01), whereas the myonuclear number significantly increased by 12% in type II fibres in placebo and remained unchanged in goserelin (P < 0.05).
    3 context sentences
    Summary · context
    Twenty-two moderately trained young men participated in this randomized, placebo-controlled, and double-blinded intervention study.
    Summary · context
    The participants were randomized to treatment with a GnRH analogue, goserelin (n = 12), which suppresses testosterone or placebo (n = 10) for 12 weeks.
    Summary · context
    The strength training period of 8 weeks started after 4 weeks of treatment and included exercises for all major muscles.
  4. 04HumanNon-randomized trialEfficacy outcome

    In young men, training increased type II satellite cell numbers by 52% with goserelin and 20% with placebo (P < 0.01).

    In plain wordsIn young men, training increased type II satellite cell numbers by 52% with goserelin and 20% with placebo.

    Peptide
    Goserelin
    Outcome
    IncreaseType II satellite cell number
    Study

    n = 22

    Comparator
    Placebo
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Training-induced increase in type II satellite cell number
    52%
    goserelin
    Training-induced increase in type II satellite cell number
    20%
    placebo

    Source sentences

    Summary
    Training increased satellite cells number in type II fibres by 20% in placebo and by 52% in goserelin (P < 0.01), whereas the myonuclear number significantly increased by 12% in type II fibres in placebo and remained unchanged in goserelin (P < 0.05).
    3 context sentences
    Summary · context
    Twenty-two moderately trained young men participated in this randomized, placebo-controlled, and double-blinded intervention study.
    Summary · context
    The participants were randomized to treatment with a GnRH analogue, goserelin (n = 12), which suppresses testosterone or placebo (n = 10) for 12 weeks.
    Summary · context
    The strength training period of 8 weeks started after 4 weeks of treatment and included exercises for all major muscles.
  5. 05HumanNon-randomized trialEfficacy outcome

    In young men receiving goserelin, type I satellite cell number did not change, as in placebo.

    In plain wordsIn young men receiving goserelin, type I satellite cell number did not change, as in placebo.

    Peptide
    Goserelin
    Outcome
    No significant changeType I satellite cell number
    Study

    n = 22

    Comparator
    Placebo
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    No changes in satellite cells and myonuclei were seen in type I fibres in either group.
    3 context sentences
    Summary · context
    Twenty-two moderately trained young men participated in this randomized, placebo-controlled, and double-blinded intervention study.
    Summary · context
    The participants were randomized to treatment with a GnRH analogue, goserelin (n = 12), which suppresses testosterone or placebo (n = 10) for 12 weeks.
    Summary · context
    The strength training period of 8 weeks started after 4 weeks of treatment and included exercises for all major muscles.
  6. 06HumanNon-randomized trialEfficacy outcome

    In young men receiving goserelin, type I myonuclear number did not change, as in placebo.

    In plain wordsIn young men receiving goserelin, type I myonuclear number did not change, as in placebo.

    Peptide
    Goserelin
    Outcome
    No significant changeType I myonuclear number
    Study

    n = 22

    Comparator
    Placebo
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    No changes in satellite cells and myonuclei were seen in type I fibres in either group.
    3 context sentences
    Summary · context
    Twenty-two moderately trained young men participated in this randomized, placebo-controlled, and double-blinded intervention study.
    Summary · context
    The participants were randomized to treatment with a GnRH analogue, goserelin (n = 12), which suppresses testosterone or placebo (n = 10) for 12 weeks.
    Summary · context
    The strength training period of 8 weeks started after 4 weeks of treatment and included exercises for all major muscles.
  7. 07HumanNon-randomized trialMechanism

    In young men receiving goserelin, microarray data indicated that low testosterone affected bone morphogenetic protein signalling.

    In plain wordsIn young men receiving goserelin, microarray data suggested changes in bone morphogenetic protein signalling with low testosterone.

    Peptide
    Goserelin
    Outcome
    Direction not reportedBone morphogenetic protein signalling
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Data from the microarray analysis indicated that low testosterone affects the bone morphogenetic proteins signalling, which might regulate proliferation vs. differentiation of satellite cells.
    3 context sentences
    Summary · context
    Twenty-two moderately trained young men participated in this randomized, placebo-controlled, and double-blinded intervention study.
    Summary · context
    The participants were randomized to treatment with a GnRH analogue, goserelin (n = 12), which suppresses testosterone or placebo (n = 10) for 12 weeks.
    Summary · context
    The strength training period of 8 weeks started after 4 weeks of treatment and included exercises for all major muscles.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.